Aarti Drugs Ltd Q4 FY26 Results & Concall Highlights: Revenue, Margins & Order Book

Published 24 May 2026 | Pharmaceuticals & Biotechnology | Market Cap: ₹3.8K Cr

Target volume growth of 8% to 10% annually, with internal ambitions of 10% to 15% growth. - Expect gradual improvement in utilization across newly commissioned facilities, especially methylamine and salicylic acid plants. - Export and regulated market sales to drive growth, with increasing U.S. Management expects gradual improvement in profitability and return ratios in the coming years supported by disciplined execution and operational excellence.

From Aarti Drugs Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.

Price

₹417

Market Cap

₹3.8K Cr

P/E Ratio

19.7

How does Aarti Drugs Ltd rank in Pharmaceuticals & Biotechnology?

Compare Aarti Drugs Ltd against every Pharmaceuticals & Biotechnology company this quarter on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

Aarti Drugs Ltd — Quarterly revenue & net profit

Revenue Net Profit

Dec 2024

Mar 2025

Jun 2025

Sep 2025

Dec 2025

Mar 2026

Reported quarterly figures (₹ Cr). Latest: revenue ₹720 Cr, net profit ₹55 Cr.

Full financials →

📊 Revenue & Sales Performance

→Target volume growth of 8% to 10% annually, with internal ambitions of 10% to 15% growth.
→Expect gradual improvement in utilization across newly commissioned facilities, especially methylamine and salicylic acid plants.
→Export and regulated market sales to drive growth, with increasing U.S. FDA and European approvals expected to boost revenues within 12-18 months.
→Formulation business targeted to grow to INR 1,000 crores in the next 3-5 years.
→Price growth expected in antibiotics segment for FY 2027, though volumes may remain flat due to high raw material and crude prices.
→EBITDA margins targeted between 13.5% to 14% in FY 2027, slightly impacted by geopolitical uncertainty but overall optimistic.
→Positive rate variances possible with continued high API prices due to West Asia conflict, supplementing volume growth.

📈 Profitability & Margins

→Management expects gradual improvement in profitability and return ratios in the coming years supported by disciplined execution and operational excellence.
→EBITDA margins targeted between 13.5% to 14% for FY 2027, slightly lower than earlier guidance of 14%-14.5% due to geopolitical uncertainties like the West Asia war.
→New projects and ramp-up of facilities like methylamine and formulation plants expected to enhance margins and revenues.
→EBITDA loss from new projects estimated around INR18-20 crores in FY 2026, expected to reduce as utilization improves.
→Formulations business with higher-margin oncology products is anticipated to grow significantly, targeting INR1,000 crores revenue in 3-5 years, contributing positively to EBITDA.
→Sustainable volume growth of 8%-10% expected, with potential to rise to 10%-15% as new capacities ramp up.
→Improved regulated market sales and export growth to support stable earnings growth.
→Overall outlook is positive with focus on long-term value creation and margin expansion as new capacities scale.

🏗️ Capital Expenditure Plans

→Planned capex of INR 300-400 crores over the next 3-4 years focusing on brownfield and quasi-greenfield expansions.
→Capex aimed at increasing existing capacity, especially in formulation business, including an additional block for formulations with EDQM certification.
→Part of the capex directed towards oncology formulations development, which requires significant investment.
→Capex linked to projects such as methylamine, salicylic acid, and formulation R&D including oncology dossiers.
→Potential for increased capex if current greenfield projects (e.g., Sayakha methylamine plant and salicylic acid plant) generate better-than-expected cash flows.
→Strategic investments in process improvements (e.g., phenol recovery equipment for salicylic acid) and antidumping measures to improve competitiveness.
→Management remains open to replacing or augmenting current capex plans if more lucrative opportunities arise.

💰 Fundraising & Capital Structure

→No specific mention of any new fundraising through debt or equity in the current transcript.
→Current consolidated long-term debt is around INR 328 crores and short-term debt around INR 248 crores.
→The company maintains a historically lowest debt-to-equity ratio as of the latest quarter.
→Capex plans of INR 300-400 crores over the next 3-4 years are expected to be funded primarily through healthy cash generation.
→Management indicated that if more lucrative opportunities arise, some capex plans might be replaced or expanded depending on cash flow improvements.
→No explicit plans announced for raising fresh debt or equity as of now.

📋 Order Book & Pipeline

- The transcript does not explicitly mention the current or expected order book or pending orders by the company. - However, on page 12, it is indicated that formulation capex is partly backed by demand visibility and customer discussions. - Capacity enhancements are based on forecasts for signed products or products with clear demand visibility once launched. - R&D capex is typically aligned with products in late-stage development or nearing approval, with most contracts signed near product readiness. - There is a strong pipeline of regulated market approvals and product launches expected within 12 to 18 months, implying a growing order flow. - The company anticipates growth in formulation sales to around INR 1,000 crores in the next 3 to 5 years, driven by increased capacity and oncology portfolio ramp-up. No quantified order book figures or explicit pending orders were provided in the transcript.

Key Metrics

What Aarti Drugs's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

Torrent Pharma. (Q4 FY26)
Consolidated revenue for Q4 FY26 up 42%, EBITDA up 41%, margins stable at ~32% (Page 2). Key concall takeaways from Torrent Pharma.'s Q4 FY26 earnings call…
Kwality Pharmaceuticals Ltd (Q4 FY26)
FY26: Achieved INR503 crores revenue; oncology contributed INR100-120 crores. Key concall takeaways from Kwality Pharmaceuticals Ltd's Q4 FY26 earnings call…
RPG Life Sciences Ltd (Q4 FY26)
Domestic formulation growth driven by strong volume expansion (~9.8% volume growth in Q4 FY26 vs 1.1% industry) and new product launches (5.1% growth vs 2%…
Sai Parenterals Ltd (Q4 FY26)
Long-term growth supported by over 50% revenue from long-term CDs contracts in regulated markets. Key concall takeaways from Sai Parenteral's's Q4 FY26…

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharma.

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Frequently Asked Questions

What were Aarti Drugs Ltd Q4 FY26 results?

What is Aarti Drugs Ltd share price analysis?

Aarti Drugs Ltd currently shows a neutral. The stock trades at a P/E of 19.7 with a market cap of ₹3,800 Cr. Investors should review the full earnings analysis for detailed insights.

Is Aarti Drugs Ltd planning capital expenditure?

Planned capex of INR 300-400 crores over the next 3-4 years focusing on brownfield and quasi-greenfield expansions.

Keep Aarti Drugs Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.